Tenderwize
Retour à la recherche

Open-house discount agreements for Naproxen

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 7 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naproxen, ATC M01AE02

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...

Only pharmaceutical companies are eligible as potential contract partners.

Submission deadline in 7 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house discount agreements for pharmaceutical products concerning Naproxen, ATC M01AE02.
  • Supply contract model for a medicinal product discount agreement under § 130a(8) SGB V, as described in the notice.
Afficher le résumé complet

Open-house supply arrangement for Naproxen (ATC M01AE02) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-exclusive, non-negotiated accession model, not a classic competitive award procedure. No contract value is stated. Submission is possible electronically with a qualified electronic signature or in paper form, with strict monthly cut-off rules and a final deadline of 05.09.2026.

Risques

For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...

Only pharmaceutical companies are eligible as potential contract partners.

Submission deadline in 7 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The signatory's authority must be evidenced by the commercial register extract; otherwise a power of attorney must be provided.

Administrative

  • Submit a signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
  • Submissions must be either handwritten on paper or electronically with a qualified electronic signature.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house discount agreements for Naproxen

Single lot covering non-exclusive open-house pharmaceutical discount agreements for the active substance Naproxen (ATC M01AE02). The lot is for supplies and performance is in Germany, Bavaria (DE212). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical terms. Lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Oct 2024 - Oct 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 05, 2026

Détails de la procédure

Date de publication
16 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
558157-2024

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30